StockData
Treace Medical Concepts, Inc. logo

Treace Medical Concepts, Inc. (TMCI) stock

TMCINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 4/3016% below fair value
$5.27−0.07 (-1.31%)

Close on Nov 13, 2026Market cap $342.73MP/E –Yield –

Treace Medical Concepts ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Treace Medical Concepts's ebitda for the twelve months ending Sep 30, 2026 was -$41.95M. For fiscal 2025 it was -$43.53M. The highest annual figure on record is $2.07M in fiscal 2020.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$43.53M–
FY2024Dec 31, 2024-$47.27M–
FY2023Dec 31, 2023-$46.08M–
FY2022Dec 31, 2022-$32.71M–
FY2021Dec 31, 2021-$15.83M-866.3%
FY2020Dec 31, 2020$2.07M–
FY2019Dec 31, 2019-$2.74M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$9.50M–
Q2 FY2026Jun 30, 2026-$13.07M–
Q1 FY2026Mar 31, 2026-$16.27M–
Q4 FY2025Dec 31, 2025-$3.11M-253.2%
Q3 FY2025Sep 30, 2025-$12.90M–
Q2 FY2025Jun 30, 2025-$14.40M–
Q1 FY2025Mar 31, 2025-$13.12M–
Q4 FY2024Dec 31, 2024$2.03M–
Q3 FY2024Sep 30, 2024-$12.98M–
Q2 FY2024Jun 30, 2024-$19.27M–
Q1 FY2024Mar 31, 2024-$17.06M–
Q4 FY2023Dec 31, 2023-$5.01M–
Q3 FY2023Sep 30, 2023-$16.25M–
Q2 FY2023Jun 30, 2023-$11.95M–
Q1 FY2023Mar 31, 2023-$12.85M–
Q4 FY2022Dec 31, 2022-$2.58M–
Q3 FY2022Sep 30, 2022-$10.92M–
Q2 FY2022Jun 30, 2022-$11.53M–
Q1 FY2022Mar 31, 2022-$7.76M–
Q4 FY2021Dec 31, 2021-$5.32M-238.5%
Q3 FY2021Sep 30, 2021-$5.26M-2319.4%
Q2 FY2021Jun 30, 2021-$3.95M–
Q1 FY2021Mar 31, 2021-$1.29M–
Q4 FY2020Dec 31, 2020$3.84M–
Q3 FY2020Sep 30, 2020$237.00K–
Q2 FY2020Jun 30, 2020-$1.12M–
Q1 FY2020Mar 31, 2020-$895.00K–

More Treace Medical Concepts figures

See a number that looks wrong?